Gent, Belgium, January 10, 2024

Aphea.Bio, a Belgium-based agricultural technology company, announced today the appointment of Hadyn Parry to its board as the new chairman.

Hadyn Parry brings a wealth of experience and expertise to Aphea.Bio, having served in several leadership roles throughout his career in the biotechnology sector. Most notably, Mr. Parry is renowned for his role as CEO of biotech firm Oxitec, where he played a pivotal role in developing revolutionary insect control solutions in both agriculture and public health. His strategic vision and operational insights have proven instrumental in achieving remarkable business success.

Johan De Saegher, outgoing Chairman of the Board, expressed his confidence in Hadyn Parry's ability to lead Aphea.Bio into its next phase of growth. "I am thrilled to hand over the reins to Hadyn, whose extensive knowledge and proven track record in the biotech industry make him an ideal candidate for this role. I have no doubt that under his leadership, Aphea.Bio will continue to revolutionize agriculture, challenge conventional practices, and deliver impactful solutions."

In his new role as Chairman of the Board of Directors, Hadyn Parry will provide strategic guidance and leadership to Aphea.Bio, ensuring the company continues to drive innovation, expand its product portfolio, and enhance its market presence. Mr. Parry's deep understanding of the agritech landscape and his commitment to sustainable agricultural practices align perfectly with Aphea.Bio's mission to develop environmentally friendly solutions for the benefit of farmers and the planet.

Hadyn Parry also expressed his excitement about working with Aphea.Bio's exceptional team. "I am honoured to join Aphea.Bio as Chairman and work alongside this talented group of scientists, researchers, and industry professionals. Aphea.Bio's unique approach is based on groundbreaking in-depth research, proprietary technology and an exemplary development pathway. I have no doubt it will play a huge part in managing the transition to sustainable agriculture. I look forward to contributing to the company's ongoing success and helping shape the future of biological crop protection."

Isabel Vercauteren, CEO at Aphea.Bio: "We are thrilled to welcome Hadyn Parry as the new Chairman of the Board of Directors. Hadyn's extensive experience and expertise in the biotech industry make him an exceptional addition to our leadership team. His strategic vision and deep understanding of sustainable agriculture align perfectly with our mission to develop innovative biological solutions for the benefit of farmers and the environment."

"I would also like to express my gratitude to Johan De Saegher for his outstanding leadership as the outgoing Chairman", Isabel said. "Under his guidance, Aphea.Bio has achieved significant milestones and established itself as a key player in the agricultural technology sector. Johan will continue to work together with Aphea.Bio being part of the Strategic Advisory Board, bringing a wealth of knowledge and experience that will continue to shape the company's strategic direction and future success."

"With Hadyn Parry's appointment, Aphea.Bio enters an exciting phase of scale-up and commercial growth. I believe that his leadership will further propel the company's mission to transform farming practices and make a positive impact on global food production. I look forward to working closely with Hadyn and the entire team as we continue to advance our pioneering bio-based solutions and contribute to a sustainable and resilient agricultural system."

About Aphea.Bio

Aphea.Bio is a fully integrated microbial product development company dedicated to food security and ensuring a safe and healthy food chain and is providing novel, science-based solutions to build the agriculture of the future: sustainable, reliable, and profitable. Located in Gent, Belgium, we have a highly dedicated and qualified team of scientist and industry experts. Based on our unique high throughput APEX® R&D platform utilising the untapped microbial space, we have been able to build a broad biostimulant and biocontrol pipeline based on naturally occurring micro-organisms.

We believe that with a fresh and sincere spirit of innovation, result-driven science, and the courage to go off the beaten track, there is fertile ground to develop efficacious biological solutions to help complement or partially replace products in the major chemical indications.

To learn more, visit www.aphea.bio or follow us on LinkedIn at www.linkedin.com/company/aphea-bio.

Aphea Bio
Charlotte Klank
Head of Regulatory Affairs | Communications
[email protected]


Data protection is important to us. You are receiving this publication on the legal basis of Article 6 para 1 lit. f GDPR ("legitimate interest"). However, if you do not wish to receive further information about Aphea.Bio, just send us a brief informal message and we will no longer process your details for this purpose. You can also find further details in our privacy statement.

Cautionary Statement Regarding Forward-Looking Statements

This document may contain forward-looking statements, which can be identified by terminology such as 'expect', 'would', 'will', 'potential', 'plans', 'prospects', 'estimated', 'aiming', 'on track' and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements. For Aphea.Bio, such risks and uncertainties include risks relating to legal proceedings, regulatory approvals, new product development, increasing competition, customer credit risk, general economic and market conditions, compliance and remediation, intellectual property rights, implementation of organizational changes, impairment of intangible assets, consumer perceptions of genetically modified crops and organisms or crop protection chemicals, climatic variations, fluctuations in exchange rates and/or commodity prices, single source supply arrangements, political uncertainty, natural disasters, and breaches of data security or other disruptions of information technology. Aphea.Bio assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

© Aphea.Bio, Technologiepark Zwijnaarde 21, 9052 Zwijnaarde.